Ro Partners with Novo Nordisk to Provide Major Savings on Wegovy® for Patients

Introduction

The healthcare landscape is rapidly evolving, with innovative companies striving to make essential treatments more accessible and affordable. Ro, a leader in direct-to-patient healthcare, has recently made headlines by introducing a significant collaboration with Novo Nordisk, the pharmaceutical giant behind the groundbreaking weight-loss medication, Wegovy®. This partnership promises to save patients substantial amounts annually, enabling more individuals to pursue their health goals without the crippling burden of high costs.

The Collaboration with Novo Nordisk

As of March 31, 2026, Ro has announced that patients can now save up to $1,200 per year on Wegovy® injections, or up to $600 for the pill form. The arrangement provides multiple payment plans, including options for three, six, and twelve-month prepaid schedules, aimed directly at cash-paying patients. This affordability initiative addresses one of the most pressing issues in modern healthcare—accessibility to essential medications.

Zach Reitano, Ro's CEO and co-founder, emphasized the importance of affordability in achieving health goals, stating, "Affordability is access, and helping patients save up to $1,200 per year on Wegovy® is a meaningful step toward breaking down that barrier for millions more people." This sentiment highlights Ro's commitment to transforming patient experiences through innovative solutions.

Wegovy®: A Game-Changer in Weight Management

Wegovy® (semaglutide) has been a groundbreaking development in the field of weight management, being the first FDA-approved GLP-1 treatment available in pill form. Since its market launch in April 2025, it has received remarkable uptake, rapidly becoming a vital tool for individuals seeking assistance with weight loss. By collaborating with Ro, Novo Nordisk is not only enhancing accessibility to Wegovy® but also ensuring that it reaches a broad audience as soon as it becomes available.

The recent launch of Wegovy® by Ro exemplifies the increasing trend where patients prefer direct-to-patient channels that streamline the acquisition of FDA-approved medicines and supporting resources. As Ed Cinca, Senior VP of Marketing at Novo Nordisk, mentioned, the transparency and flexibility in payment options offered by Ro allow patients greater control over their health care journey.

Exciting New Offerings from Ro

In addition to Wegovy discounts, Ro is also set to introduce new savings options for its Body Membership plan in April. This membership allows patients access to continuous care, includes features like 24/7 messaging for support, side effect monitoring, coaching, and progress tracking—essential services for individuals committed to managing their health effectively. This proactive approach can significantly enhance user engagement and results for those utilizing GLP-1 medications.

Furthermore, Ro's GLP-1 Insurance Checker tool has provided invaluable support to over 2 million individuals, helping them navigate their insurance benefits to secure medications at the lowest prices—whether through insurance or via direct purchase.

Conclusion

Ro’s collaboration with Novo Nordisk represents a significant leap toward ensuring that life-changing medications like Wegovy® are not just available but also affordable to a wide demographic. With the potential for savings amounting to $1,200 annually, patients now have more opportunities to focus on their health without the looming financial stress of medication costs. Ro continues to set a high standard in patient-centered care, making healthcare more accessible, transparent, and user-friendly, paving the way for the future of health management.

For those interested in learning more about Ro's full suite of GLP-1 options and membership features, visit Ro's official site.